Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.33 |
| ▸ | PLD2 | O14939 | 6/20 | 0.32 |
| ▸ | PLD1 | Q13393 | 6/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL755765 | 1.00 | BACE1 (0.33) | BACE1PLD2PLD1TMEM97SIGMAR1 | |
| SCHEMBL758912 | 0.95 | TMEM97 (0.35) | BACE1PLD2PLD1TMEM97SIGMAR1 | |
| SCHEMBL755756 | 0.95 | TMEM97 (0.35) | BACE1PLD2PLD1TMEM97SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL5616568 | 0.86 | BACE1 (0.36) | BACE1TMEM97SIGMAR1BACE2 | |
| Trifluoroacetic Acid SCHEMBL757785 | 0.86 | BACE1 (0.36) | BACE1TMEM97SIGMAR1BACE2 | |
| SCHEMBL756435 | 0.81 | BACE1 (0.38) | BACE1TMEM97SIGMAR1BACE2 | |
| SCHEMBL8238893 | 0.81 | BACE1 (0.38) | BACE1TMEM97SIGMAR1BACE2 | |
| SCHEMBL755103 | 0.78 | BACE1 (0.55) | BACE1 | |
| SCHEMBL757309 | 0.78 | BACE1 (0.55) | BACE1 | |
| SCHEMBL755104 | 0.78 | BACE1 (0.55) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | BACE1 1/4885PLD2 3358/4885PLD1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.